10,172 Shares in Ionis Pharmaceuticals, Inc. $IONS Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 10,172 shares of the company’s stock, valued at approximately $665,000.

A number of other institutional investors also recently bought and sold shares of IONS. Steigerwald Gordon & Koch Inc. acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter valued at approximately $25,000. Golden State Wealth Management LLC lifted its position in Ionis Pharmaceuticals by 198.4% during the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock valued at $25,000 after purchasing an additional 250 shares during the period. Mather Group LLC. purchased a new stake in Ionis Pharmaceuticals in the third quarter valued at $27,000. Allworth Financial LP boosted its holdings in Ionis Pharmaceuticals by 231.8% in the second quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after purchasing an additional 517 shares during the last quarter. Finally, Meeder Asset Management Inc. grew its position in Ionis Pharmaceuticals by 620.2% during the 3rd quarter. Meeder Asset Management Inc. now owns 713 shares of the company’s stock worth $47,000 after purchasing an additional 614 shares during the period. 93.86% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ionis Pharmaceuticals

In related news, CEO Brett P. Monia sold 29,430 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $85.79, for a total value of $2,524,799.70. Following the transaction, the chief executive officer directly owned 254,497 shares of the company’s stock, valued at approximately $21,833,297.63. This trade represents a 10.37% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Eugene Schneider sold 6,179 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $83.45, for a total value of $515,637.55. Following the completion of the sale, the executive vice president owned 69,702 shares in the company, valued at approximately $5,816,631.90. The trade was a 8.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 481,356 shares of company stock valued at $38,987,621. Corporate insiders own 2.71% of the company’s stock.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS opened at $83.15 on Monday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 2.78 and a current ratio of 2.79. The firm has a fifty day moving average of $80.93 and a 200 day moving average of $70.88. The firm has a market cap of $13.47 billion, a PE ratio of -49.20 and a beta of 0.29. Ionis Pharmaceuticals, Inc. has a one year low of $23.95 and a one year high of $86.74.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, January 22nd. Needham & Company LLC boosted their price target on Ionis Pharmaceuticals from $78.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Morgan Stanley upped their price objective on Ionis Pharmaceuticals from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. TD Cowen reaffirmed a “buy” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, December 3rd. Finally, Leerink Partners increased their price target on shares of Ionis Pharmaceuticals from $85.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $86.95.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.